Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Sohn Conference: Accelerating Translation of Pediatric Cancer Research

Sohn Conference: Accelerating Translation of Pediatric Cancer Research

Monday, February 26, 2018 - Wednesday, February 28, 2018

The Royal Society, 6-9 Carlton House Terrace, London, United Kingdom

This event is not organized or endorsed by The Royal Society

Presented By

The Sohn Conference Foundation

The New York Academy of Sciences

 

Pediatric cancer is the leading cause of death by disease past infancy among children in the United States and Europe. Despite prevailing increases in overall survival rates, it continues to be one of the most challenging diseases to treat. Our basic understanding of pediatric cancer biology has improved, but high rates of relapse remain; and 20% of pediatric cancer patients do not respond to therapy, ultimately dying from their disease. We now understand that childhood cancers are genetically distinct from their adult counterparts, and that current treatments developed for adults are particularly harsh on growing children, causing severe side effects. Thus, there is a critical need to refine established therapeutic approaches for this vulnerable population to improve treatment for patients around the world.

This 2.5-day international conference will advance the dialogue from the first meeting presented jointly by the Sohn Conference Foundation and the New York Academy of Sciences in 2016, the Sohn Conference: Pediatric Cancer in a Post-genomic World. Leading researchers, clinicians, pediatric cancer advocates, and industry and governmental stakeholders from around the globe will reconvene, this time in London, England, to discuss strategies to help bridge the gap between basic research discoveries and treatments for pediatric and adolescent cancer patients. The aim will be to provide a platform for these leaders from different countries and continents to share promising new findings, identify best practices, and develop a unified approach. Conference speakers will present emerging basic and clinical cutting edge research in pediatric cancers on topics including somatic and germline alterations, genomics and epigenomics, opportunities and challenges in immunotherapy, developmental biology, biology of tumor progression and relapse, technologies for non-invasive disease monitoring, biological determinants of survival, and challenges in clinical trial design and drug development.

Registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.

Registration

Member
By 01/15/2018
$205
After 01/15/2018
$240
Onsite
$275
Nonmember Academia, Faculty, etc.
By 01/15/2018
$255
After 01/15/2018
$290
Onsite
$380
Nonmember Corporate, Other
By 01/15/2018
$360
After 01/15/2018
$420
Onsite
$520
Nonmember Not for Profit
By 01/15/2018
$255
After 01/15/2018
$290
Onsite
$380
Nonmember Student, Undergrad, Grad, Fellow
By 01/15/2018
$140
After 01/15/2018
$170
Onsite
$225
Member Student, Post-Doc, Fellow
By 01/15/2018
$105
After 01/15/2018
$135
Onsite
$185

Organizers

John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
Louis Chesler, PhD, MD, FRCPCH, The Royal Marsden; The Institute of Cancer Research, London, United Kingdom
Louis Chesler, PhD, MD, FRCPCH, The Royal Marsden; The Institute of Cancer Research, London, United Kingdom
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute; University of Cambridge, United Kingdom
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute; University of Cambridge, United Kingdom
Lee J. Helman, MD, Children’s Hospital Los Angeles and the Norris Comprehensive Cancer Center, University of Southern California
Lee J. Helman, MD, Children’s Hospital Los Angeles and the Norris Comprehensive Cancer Center, University of Southern California
Andrew Kung, MD, PhD, Memorial Sloan Kettering Cancer Center
Andrew Kung, MD, PhD, Memorial Sloan Kettering Cancer Center
John M. Maris, MD, Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
John M. Maris, MD, Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
Kathy Pritchard-Jones, BM BCh, PhD, FRCPCH, University College London Great Ormond Street Institute of Child Health, United Kingdom
Kathy Pritchard-Jones, BM BCh, PhD, FRCPCH, University College London Great Ormond Street Institute of Child Health, United Kingdom
Poul Sorensen, MD, PhD, FRCPC¸ British Columbia Cancer Research Centre; The University of British Columbia, Canada
Poul Sorensen, MD, PhD, FRCPC¸ British Columbia Cancer Research Centre; The University of British Columbia, Canada
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Lauren Breslow, JD, MPH, The Sohn Conference Foundation
Lauren Breslow, JD, MPH, The Sohn Conference Foundation
Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences
Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences
Alison Carley, PhD, The New York Academy of Sciences
Alison Carley, PhD, The New York Academy of Sciences
Jennifer Lazar Schiamberg, The Sohn Conference Foundation
Jennifer Lazar Schiamberg, The Sohn Conference Foundation

Keynote Speakers

Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute;  University of Cambridge, United Kingdom
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute; University of Cambridge, United Kingdom
Mignon Lee-Cheun Loh, MD, Benioff Children's Hospital and the Helen Diller Family Cancer Center, University of California, San Francisco
Mignon Lee-Cheun Loh, MD, Benioff Children's Hospital and the Helen Diller Family Cancer Center, University of California, San Francisco

Speakers and Panelists

John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute
Smita Bhatia, MD, MPH,  The University of Alabama at Birmingham
Smita Bhatia, MD, MPH, The University of Alabama at Birmingham
Sam Behjati, PhD, Wellcome Sanger Institute and University of Cambridge, United Kingdom
Sam Behjati, PhD, Wellcome Sanger Institute and University of Cambridge, United Kingdom
Patricia Blanc, Imagine for Margo, France
Patricia Blanc, Imagine for Margo, France
Kevin M. Brindle, PhD, FMedSci, Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
Kevin M. Brindle, PhD, FMedSci, Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
Stefan Burdach, MD, PhD, Technical University of Munich, Germany
Stefan Burdach, MD, PhD, Technical University of Munich, Germany
Louis Chesler, PHD, MD, FRCPCH, The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
Louis Chesler, PHD, MD, FRCPCH, The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
Florent de Vathaire, PhD, Gustave Roussy Institute, France
Florent de Vathaire, PhD, Gustave Roussy Institute, France
 Lee Helman, MD Children’s Hospital of Los Angeles, University of Southern California
Lee Helman, MD Children’s Hospital of Los Angeles, University of Southern California
Andrew Kung, MD, PhD Memorial Sloan Kettering Cancer Center
Andrew Kung, MD, PhD Memorial Sloan Kettering Cancer Center
David Malkin, MD, FRCP(C), FAAP, The Hospital for Sick Children, Canada
David Malkin, MD, FRCP(C), FAAP, The Hospital for Sick Children, Canada
John Maris, MD, The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
John Maris, MD, The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania
Yael P. Mossé, MD, Children’s Hospital of Philadelphia
Yael P. Mossé, MD, Children’s Hospital of Philadelphia
Stefan Pfister, MD, Heidelberg University Hospital and German Cancer Research Center, Germany
Stefan Pfister, MD, Heidelberg University Hospital and German Cancer Research Center, Germany
Kathy Pritchard Jones, BMBCh, PhD, Great Ormond Street Institute of Child Health, University College London, United Kingdom
Kathy Pritchard Jones, BMBCh, PhD, Great Ormond Street Institute of Child Health, University College London, United Kingdom
Raphaël Rousseau, MD, PhD, Gritstone Oncology, Inc.
Raphaël Rousseau, MD, PhD, Gritstone Oncology, Inc.
Gudrun Schleiermacher, MD, PhD, Curie Institute, France
Gudrun Schleiermacher, MD, PhD, Curie Institute, France
Poul Sorensen, MD, PhD, British Columbia Cancer Research Centre and University of British Columbia, Canada
Poul Sorensen, MD, PhD, British Columbia Cancer Research Centre and University of British Columbia, Canada
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital
Uri Tabori, MD, The Hospital for Sick Children, Canada
Uri Tabori, MD, The Hospital for Sick Children, Canada
Michael Taylor, MD, PhD, FRCS(C), The Hospital for Sick Children, Canada
Michael Taylor, MD, PhD, FRCS(C), The Hospital for Sick Children, Canada
Eleni Tomazou, PhD, Children's Cancer Research Institute (CCRI), Austria
Eleni Tomazou, PhD, Children's Cancer Research Institute (CCRI), Austria
Matthew Vander Heiden, MD, PhD, Koch Institute for Integrative Cancer Research at MIT
Matthew Vander Heiden, MD, PhD, Koch Institute for Integrative Cancer Research at MIT
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
Paul Workman, FRS, FRSC, FMedSci, The Institute of Cancer Research, London, United Kingdom
Paul Workman, FRS, FRSC, FMedSci, The Institute of Cancer Research, London, United Kingdom

Presented by

The Sohn Conference Foundation supports innovative initiatives that promote its mission to treat and cure pediatric cancer.  Toward this goal, the Foundation seeks to embolden elite scientists researching pediatric cancers to collaborate across institutions and, with this Conference, across nations, to further research toward cures.  This Conference is also a meaningful reflection of the Foundation’s unique philanthropic model: the Foundation raises funds by convening leading investment professionals to share their best ideas and fundraise for the cause of pediatric cancer research.  It is therefore the Foundation’s privilege to partner with the New York Academy of Sciences to convene the world’s scientific leaders who will change the course of treating pediatric cancer, ultimately, saving more children from cancer and treatment side-effects.

Monday

February 26, 2018

1:10 PM

Registration

1:30 PM

Introduction and Welcome Remarks

Speakers

Piers Butler
The Sohn Foundation London
Melanie Brickman Borchard, PhD, MSc
The New York Academy of Sciences
1:40 PM

Day 1 Keynote Address: Planes, Trains and Different-fields

Speaker

Richard Gilbertson, MD, PhD
Cancer Research UK Cambridge Institute and University of Cambridge, United Kingdom

Session I: Inherited Predisposition to Childhood Cancers

Session Chairperson
John Maris, MD, The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, United States
2:20 PM

Li-Fraumeni Syndrome: The Molecular Basis of Cancer Predisposition, Early Detection and Prevention

Speaker

David Malkin, MD, FRCP(C), FAAP
The Hospital for Sick Children, Canada
2:45 PM

Revealing the Identity of Cancer Cells

Speaker

Sam Behjati, PhD
Wellcome Sanger Institute and University of Cambridge, United Kingdom
3:10 PM

Networking Coffee Break

Session II: Somatic Alterations in Pediatric Cancers: Genomics and Epigenomics

Session Chairperson
Lee Helman, MD, Children’s Hospital of Los Angeles, United States
3:40 PM

New Vulnerabilities in Pediatric Cancer

Speaker

Kimberly Stegmaier, MD
Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital, United States
4:05 PM

Ewing Sarcoma: An Enhancer Disease with Widespread Epigenetic Heterogeneity

Speaker

Eleni Tomazou, PhD
Children's Cancer Research Institute (CCRI), Austria
4:30 PM

Next-generation Diagnostics in Pediatric Neurooncology

Speaker

Stefan Pfister, MD
German Cancer Research Center (DKFZ), Germany
4:55 PM

Closing Remarks

5:05 PM

Day 1 Ends

Tuesday

February 27, 2018

9:00 AM

Networking Breakfast, Poster Set Up

Session III: Opportunities and Challenges in Immunotherapy for the Treatment of Pediatric Cancers

Session Chairperson
Kimberly Stegmaier, MD, Dana-Farber Cancer Institute, Harvard Medical School, and Boston Children's Hospital, United States
9:30 AM

Targeting Childhood Solid Cancers with Engineered T Cells

Speaker

John Anderson, PhD
University College London Great Ormond Street Institute of Child Health, United Kingdom
9:55 AM

Pediatric Cancer Immunotherapy: Not a Trickle Down from Medical Oncology

Speaker

John Maris, MD
The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, United States
10:20 AM

The Role of Hypermutation and Replication Repair Deficiency in Response of Childhood Cancers to Immune Checkpoint Inhibitors

Speaker

Uri Tabori, MD
The Hospital for Sick Children, Canada
10:45 AM

Networking Coffee Break

Session IV: Incorporating Developmental Biology into Our Understanding of Pediatric Cancers

Session Chairperson
Richard Gilbertson, MD, PhD, Cancer Research UK Cambridge Institute and University of Cambridge, United Kingdom
11:15 AM

Targeting Neuroblastoma — Mouse Models to Therapeutics for ALK and MYCN

Speaker

Louis Chesler, PHD, MD, FRCPCH
The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
11:40 AM

Targeting Chromatin Complexes in Pediatric Cancer

Speaker

Scott Armstrong, MD, PhD
Dana-Farber Cancer Institute, United States
12:05 PM

Networking Lunch and Poster Viewing

Session V: Hot Topic Talks from Submitted Abstracts

Session Chairperson
Poul Sorensen, MD, PhD, British Columbia Cancer Research Centre and University of British Columbia, Canada
1:20 PM

Tumor Mutational Burden Analysis of Pediatric Tumors Provides a Diagnostic Tool for Germline Predisposition and Reveals Novel Candidates for Immune Checkpoint Inhibition

Speaker

Brittany Campbell, PhD
The Hospital for Sick Children, Canada
1:35 PM

Targeting Metabolic Adaptation in MYCN Amplified Pediatric Neuroblastoma

Speaker

Alberto Delaidelli, MD
British Columbia Cancer Research Centre and University of British Columbia, Canada

Session VI: Emerging Biology of Tumor Progression and Relapse

Session Chairperson
Gilles Vassal, MD, PhD, Gustave Roussy Institute, France
1:50 PM

Stress-mediated Translational Control of Sarcoma Metastasis

Speaker

Poul Sorensen, MD, PhD
British Columbia Cancer Research Centre and University of British Columbia, Canada
2:15 PM

Approaches to Target Cancer Metabolism

Speaker

Matthew Vander Heiden, MD, PhD
Koch Institute for Integrative Cancer Research at MIT, United States
2:40 PM

Heterogeneity through Space and Time Drive the Clinical Behavior of Childhood Brain Cancers

Speaker

Michael D. Taylor, MD, PhD, FRCS(C)
The Hospital for Sick Children, Canada
3:05 PM

Patient-driven Discovery in Pediatric Oncology

Speaker

Andrew Kung, MD, PhD
Memorial Sloan Kettering Cancer Center, United States
3:30 PM

Day 2 Closing Remarks

3:35 PM

Networking Reception and Poster Session

5:00 PM

Day 2 Ends

Wednesday

February 28, 2018

9:00 AM

Networking Breakfast

9:30 AM

Day 3 Keynote Address: Juvenile Myelomonocytic Leukemia: Learning from Patients in a World without Walls

Speaker

Mignon Lee-Cheun Loh, MD
Benioff Children's Hospital and the Helen Diller Family Cancer Center, University of California, San Francisco, United States
10:10 AM

Networking Coffee Break

Session VII: Strategies and Challenges in Clinical Trial Design and Drug Development

Session Chairperson
John Anderson, PhD, University College London Great Ormond Street Institute of Child Health, United Kingdom
10:40 AM

Innovative Designs and Strategy to Accelerate Translation of Pediatric Cancer Research into New Effective Therapies

Speaker

Gilles Vassal, MD, PhD
Gustave Roussy Institute, France
11:05 AM

Elucidating and Targeting Evolving Therapy Resistance in Neuroblastoma

Speaker

Yael P. Mossé, MD
Children's Hospital of Philadelphia, United States
11:30 AM

Innovative Clinical Trials and New Drug Development: A Pharmaceutical Industry Perspective

Speaker

Raphaël Rousseau, MD, PhD
Gritstone Oncology, Inc., United States
11:55 AM

Panel Discussion: Accelerating Drug Development

Speakers

Kathy Pritchard Jones, BMBCh, PhD (Moderator)
Great Ormond Street Institute of Child Health, University College London, United Kingdom
Patricia Blanc
Imagine for Margo, France
Stefan Burdach, MD, PhD
Technical University of Munich, Germany
Raphaël Rousseau, MD, PhD
Gritstone Oncology, Inc., United States
Paul Workman, FRS, FRSC, FMedSci
The Institute of Cancer Research, London, United Kingdom
12:45 PM - 1:55 PM

Networking Lunch

Early Career Investigator and Underrepresented Minority Mentoring Lunch

For Graduate Students, Post-doctoral Fellows, and Junior Faculty

Session VIII: Emerging Technologies in Non-invasive Disease Monitoring

Session Chairperson
Louis Chesler, PHD, MD, FRCPCH, The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
1:55 PM

Development of Liquid Biopsies/cfDNA in Osteosarcoma: An Unmet Need

Speaker

Lee Helman, MD
Children’s Hospital of Los Angeles, University of Southern California, United States
2:20 PM

Clonal Evolution in Pediatric Solid High Risk Cancers Based on Sequential Analysis of Circulating Tumor DNA

Speaker

Gudrun Schleiermacher, MD, PhD
Curie Institute, France
2:45 PM

Imaging Tumor Cell Metabolism — From Mouse to Man

Speaker

Kevin Brindle, PhD, FMedSci
University of Cambridge, United Kingdom
3:10 PM

Networking Coffee Break

Session IX: Hot Topic Talks from Submitted Abstracts

Session Chairperson
Andrew Kung, MD, PhD, Memorial Sloan Kettering Cancer Center, United States
3:35 PM

The Orally Bioavailable Small Molecule CDK2/9 Inhibitors CYC065 and CCT68127 Are Potent Inhibitors of MYCN via Transcriptional Repression

Speaker

Evon Poon, PhD
The Royal Marsden and The Institute of Cancer Research, London, United Kingdom
3:50 PM

Intellectual Outcome in Children with Sensorineural Hearing Loss Following Treatment for Malignant Embryonal Brain Tumors

Speaker

Iska Moxon-Emre, MSc, MA
The Hospital for Sick Children, Canada

Session X: Biological Determinants of Late Effects in Pediatric Cancer Survivors

Session Chairperson
Kathy Pritchard Jones, BM BCh, PhD, FRCPCH, Great Ormond Street Institute of Child Health, University College London, United Kingdom
4:05 PM

Mitigating the Risk of Treatment-related Complications in Childhood Cancer Survivors — Are We There Yet?

Speaker

Smita Bhatia, MD, MPH
The University of Alabama at Birmingham, United States
4:30 PM

Constitutional DNA Variants and Other Biomarkers Predictive of Late Effects in Childhood Cancer Survivors

Speaker

Florent de Vathaire, PhD
Gustave Roussy Institute, France
4:55 PM

Day 3 Closing Remarks

5:00 PM

Conference Adjourns